Abstract:Introduction The incidence and risk factors for venous thromboembolism (VTE) in hospitalized patients with cirrhosis are poorly understood. Aim We investigated the incidence, risk factors, and clinical impact of VTE in a prospective cohort of patients with cirrhosis. Materials and Methods Patients were recruited at hospital admission and prospectively followed during hospitalization for development of VTE. Patients receiving anticoagulation and those with cancer were not eligible. Associations with baseline characteristics and 3-months mortality were explored. Hazard ratios (HR) and 95% CIs were calculated using Cox regression. Results We included 461 patients (median age 61 years old; 67% male; 52% with alcohol-related cirrhosis). Ascites ± hepatic encephalopathy were the most common reasons for admission. The median MELD score was 18 (12-24); 11% of patients were Child-Pugh A, 41% were Child-Pugh B, and 48% were Child-Pugh C. During hospitalization, 28 (6.1%) patients experienced VTE. Multivariate analysis showed that Child-Pugh C vs. A/B (HR: 5.25; 95% CI: 1.75-15.73), reduced mobility (HR: 4.21; 95% CI: 1.83-9.67), and bacterial infections (HR: 2.35; 95% CI: 1.06-5.12) were independent predictors of VTE. A predictive model (CirrhosisThrombosisModel) based on these variables accurately identified patients at risk (sensitivity 96.3%, specificity 66.7%) (Table). The AUROC of CiThroModel was significantly higher compared with the Padua prediction score (0.842 [0.784-0.899] vs. 0.753 [0.669-0.837]; p=0.04). Regarding 3-month mortality, a multivariate Cox regression model including Child-Pugh stage, AKI, infections, and VTE showed that Child-Pugh stage was the only independent predictor of death. Conclusion Hospitalized patients with cirrhosis are at risk of VTE. Reduced mobility, Child-Pugh stage C, and bacterial infections are independently associated with the risk of developing VTE, thus allowing risk stratification. The CiThroModel can be used to identify the patients at higher risk and guide thromboprophylaxis. Whether VTE in cirrhosis is independently linked to mortality requires further investigation.

Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications

The Molecular Mechanisms of Portal Vein Thrombosis in Hepatocellular Carcinoma

Hematological abnormalities in liver cirrhosis

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Mechanisms and management of thrombosis in cancer: focus on gastrointestinal malignancies

The clinical features of venous thromboembolism in patients with cirrhosis

[Coagulation disorders in liver cirrhosis - Diagnostics and management]

Exploring Haematological Complications in Cirrhosis of the Liver: A Comprehensive Review

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

CiThroModel improves the prediction of venous thromboembolism in hospitalized patients with cirrhosis

Direct oral anticoagulants in cirrhosis: Rationale and current evidence

Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis

Prevention and management of venous thrombosis in patients with cirrhosis

Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases

Thrombosis and bleeding in hematological malignancy

Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH

A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?

Hepatocellular carcinoma: clinical frontiers and perspectives

Low-molecular-weight heparins and cancer: Focus on antitumoral effect

Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis

Cancer and liver cirrhosis: implications on prognosis and management